NanoLogix Announces European Clinical Trial of Its Rapid Detection Kits
June 07 2011 - 11:45AM
Business Wire
NanoLogix (PINK SHEETS: NNLX), a biotechnology innovator in the
rapid detection and identification of live-cell bacteria and
microorganisms, announced today its BioNanoFilter (BNF) technology
will undergo a clinical trial, led by Dr. Gian Carlo Di Renzo of
the University of Perugia in Italy. The 300 patient trial will
study the speed and accuracy of NanoLogix technology compared to
current methods in the detection and identification of Group B
Streptococcus (GBS) in pregnant women. Initial BNF results on GBS
from the University of Texas Health Science Center-Houston show
detection and identification within two to six hours. This is eight
to twenty-four times faster than conventional methods. The trial
will be the second clinical trial conducted on the NanoLogix BNF
technology for Group B Strep. Results from this clinical trial will
accelerate the approval of the BNF kits for use in Europe, North
Africa and the Middle East.
Conventional technology can take at least 48-72 hours to return
results for Group B Strep. Often during this waiting period it is
recommended that physicians treat patients empirically with
antibiotics if they fall into specified “at risk” categories for
being colonized with GBS. This practice protects the mother from
health risks and the unborn child from life threatening illnesses
related to Group B Strep. However, it can also lead to the
development of antibiotic resistance in GBS strains.
About 30 percent of reproductive age women carry GBS, which can
cause life-threatening infections such as sepsis, meningitis and
pneumonia in newborns, if their mothers are not treated prior to
delivery. In the U.S., delivery without treatment results in around
8,000 newborns being infected each year. The Centers for Disease
Control guidelines for the prevention of neonatal GBS call for
testing all pregnant women for GBS between 35 and 37 weeks. In
2009, just over 4 million women gave birth in the U.S. alone.
“We are excited to have our BioNanoFilter technology undergo a
clinical trial in Europe,” said NanoLogix CEO Bret Barnhizer. “We
expect this European clinical trial to pave the way for
certification and validation of our rapid detection technologies
there, as well as in North Africa and the Middle East. We thank Dr.
Di Renzo and the other physicians and technicians who are involved
in the trial.”
Success at 2011 American Society for Microbiology General
Meeting
NanoLogix had a very successful exhibit at the American Society
for Microbiology General Meeting in New Orleans last week. Interest
was renewed with a Japanese firm and new interest was generated
from various parties including the US Navy, US Army, US Department
of Agriculture (USDA), and the Centers for Disease Control and
Prevention (Atlanta).
NanoLogix Shipping Product For Testing
Based on the success of the ASM and other business building
activities, the company is shipping BNP and BNF kits for testing
and use to the USDA and a major food processing company, during the
month of June. The kits are to be used for internal food processing
screening purposes.
Update on University of Texas Health Science Center
Trial
The first phase of the University of Texas Health Science Center
clinical trial was accepted for publication by a major
peer-reviewed journal. The name of the journal will be announced
upon publication of the UTHSC paper.
For more information, go to www.nanologix.com
About NanoLogix, Inc.
NanoLogix is a biotechnology company focused primarily on rapid
diagnostics. Its products offer accelerated detection and
identification of microorganisms. In addition to medical and
homeland security applications, NanoLogix technology is applicable
in pharmaceutical, industrial, veterinary and environmental
testing. Patents granted to NanoLogix can be used in the areas of
applied microbiology, soil microbiology and bioremediation,
microbial physiology, molecular biology, pharmacology,
pharmaco-kinetics, and antibiotic sensitivity. For more information
visit www.nanologix.com.
This press release contains statements, which may constitute
"forward- looking statements" within the meaning of the Securities
Act of 1933 and the Securities Exchange Act of 1934, as amended by
the Private Securities Litigation Reform Act of 1995. Those
statements include statements regarding the intent, belief or
current expectations of NanoLogix, Inc., and members of its
management as well as the assumptions on which such statements are
based. Prospective investors are cautioned that any such
forward-looking statements are not guarantees of future performance
and involve risks and uncertainties, and that actual results may
differ materially from those contemplated by such forward-looking
statements. The Company undertakes no obligation to update or
revise forward-looking statements to reflect changed assumptions,
the occurrence of unanticipated events or changes to future
operating results.
NanoLogix (CE) (USOTC:NNLX)
Historical Stock Chart
From Jun 2024 to Jul 2024
NanoLogix (CE) (USOTC:NNLX)
Historical Stock Chart
From Jul 2023 to Jul 2024